NASDAQ · NAMS
Healthcare · Biotechnology
$21.58
Up+$0.32 (+1.48%)
Updated Oct 12, 2026, 10:02 AM
SID Score
3.8/10
Composite research score
Smart Money
58/100
Neutral
Price performance · NAMS
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
NAMS closed at $21.58 after 20 trading sessions, down 3.51% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $21.25 | $21.79 | $21.02 | $21.575 | 1.27M |
| Oct 8, 2026 | $22.00 | $22.13 | $20.91 | $21.26 | 1.67M |
| Oct 7, 2026 | $22.07 | $22.72 | $21.85 | $22.13 | 1.38M |
| Oct 6, 2026 | $23.06 | $23.11 | $21.4442 | $22.27 | 1.27M |
| Oct 5, 2026 | $22.84 | $23.34 | $22.23 | $22.80 | 1.18M |
| Oct 2, 2026 | $24.60 | $24.75 | $22.67 | $23.20 | 1.55M |
| Oct 1, 2026 | $24.23 | $24.835 | $24.06 | $24.16 | 1.63M |
| Sep 30, 2026 | $24.00 | $25.12 | $23.96 | $24.32 | 2.27M |
| Sep 29, 2026 | $23.52 | $24.54 | $23.26 | $23.81 | 1.08M |
| Sep 28, 2026 | $22.50 | $24.21 | $22.25 | $23.58 | 2.06M |
| Sep 25, 2026 | $22.93 | $22.96 | $22.35 | $22.58 | 1.14M |
| Sep 24, 2026 | $22.47 | $23.19 | $21.95 | $22.74 | 1.82M |
| Sep 23, 2026 | $23.31 | $23.32 | $22.08 | $22.68 | 2.27M |
| Sep 22, 2026 | $22.91 | $23.725 | $22.13 | $23.32 | 2.87M |
| Sep 21, 2026 | $22.95 | $23.20 | $21.68 | $22.58 | 3.53M |
| Sep 18, 2026 | $21.62 | $22.50 | $21.29 | $22.49 | 2.08M |
| Sep 17, 2026 | $21.59 | $23.1125 | $21.455 | $21.93 | 2.31M |
| Sep 16, 2026 | $22.07 | $22.15 | $21.02 | $21.18 | 1.24M |
| Sep 15, 2026 | $22.32 | $22.6247 | $21.08 | $21.16 | 1.73M |
| Sep 14, 2026 | $22.96 | $22.96 | $22.34 | $22.36 | 1.08M |
The latest Smart Investors Daily articles mentioning NAMS.
Company
Market Activity
Research & News
NAMS research
Company profile and research snapshot.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 5, 2026 | RBC Capital | Outperform | — |
| Sep 8, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 6, 2026 | RBC Capital | Outperform | — |
| Jun 30, 2026 | RBC Capital | Outperform | — |
| Feb 19, 2026 | Guggenheim | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 5, 2026
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and lowers the price target from $50 to $42.
Yahoo · Oct 2, 2026
Activists also report to the SEC on NewAmsterdam Pharma, Tennant, Colliers International Group, and Kinetik Holdings.
Yahoo · Oct 2, 2026
NAARDEN, The Netherlands and MIAMI, Oct. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s
Yahoo · Sep 29, 2026
- SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeable memory or functional symptoms- - The study will evaluate changes in blood-based biomarkers associated with Alzheimer’s disease, including p-tau 217, and additional cognitive and functional measures- NAARDEN, the Netherlands and MIAMI, Sept. 29, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a lat
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NAMS.
